[A feasibility study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for Japanese patients with advanced colorectal cancer].
Tatsushi Shingai(Kinki Central Hospital), Masahiko Yano(Nagoya Sangyo University), Masayuki Ohue(Hyogo Medical University), Yoji Takeuchi(Osaka International Cancer Institute), Daisuke Sakai, Sachiko Yamamoto(Osaka International Cancer Institute), Tetsuhiro Yoshinami, Naotoshi Sugimoto(Osaka International Cancer Institute), Toshinari Yagi, Koji Higashino, Shingo Noura(Osaka Rosai Hospital)
PubMed
February 1, 2015
Cited by 0
Related Papers
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2019|282
Implications of Nectin-like Molecule-2/IGSF4/RA175/SgIGSF/TSLC1/SynCAM1 in Cell-Cell Adhesion and Transmembrane Protein Localization in Epithelial Cells
|Journal of Biological Chemistry|2003|231
Systematic review and meta-analysis of endoscopic submucosal dissection versus transanal endoscopic microsurgery for large noninvasive rectal lesions
|Surgical Endoscopy|2013|171
Risk of Recurrence in a Long-term Follow-up After Surgery in 417 Patients With Hepatitis B- or Hepatitis C-Related Hepatocellular Carcinoma
|Annals of Surgery|2006|159
S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species
|Cardiovascular Research|2009|143